Page 2 - Recent Pipeline News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

RUBY-3, a basket study of povetacicept in autoimmune glomerulonephritis, has initiated patient enrollment; RUBY-4, a basket study of povetacicept in autoimmune cytopenias, targets initiation in Q2. | March 23, 2023

United statesJames tumlinExchange commissionList of company publicationsAlpine immune sciences incAmerican academy of dermatology annual meeting onSecurities exchangeAlpine immune sciencesNephronet clinical trials consortiumExecutive chairmanChief executive officerMedical directorEmory university schoolRecent pipelineView publicationAmerican academy

Alpine Immune Sciences (ALPN) Reports Q4, Provides Corporate Update

Alpine Immune Sciences (ALPN) Reports Q4, Provides Corporate Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesTemre johnsonJames tumlinList of company publicationsExchange commissionAlpine immune sciencesNephronet clinical trials consortiumAlpine immune sciences incSecurities exchangeAmerican academy of dermatology annual meeting onWall streetImmune sciencesExecutive chairmanChief executive officerMedical directorEmory university school

LAVA Therapeutics Provides Business Update and Reports Second Quarter Financial Results

13.09.2022 - Initial Phase 1/2a clinical findings for LAVA-051 in patients with chronic lymphocytic leukemia and multiple myeloma patients demonstrated encouraging anti-tumor activity and safety profile; on track to report additional clinical data in fourth .

United statesNoord hollandBenjamin winogradArnon katerStagegammabodypipeline developmentAmsterdam university medical centerDrug administrationRecent pipelineImmaterial misstatementsJanssen biotechConsolidated interim statements

Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2022 Financial Results

SEATTLE (BUSINESS WIRE) Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the second quarter ended June 30,.

United statesViela bioAlex sharifAndrew sandlerKiadis pharmaAmerican society of clinical oncologyMerck co incSanofi companyCompany abbvieCompany complete responseAlpine immune sciencesAlpine immune sciences incMerck sharp dohme corpEuropean alliance of associationsExchange commissionCorporate development

Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

11.08.2022 - Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the second quarter ended June .

United statesAura biosciences incAmerican society of clinical oncologyExchange commissionInternational society of ocular oncologyAssociation of researchDivision of oncologyRecent pipelineInternational societyOcular oncologyAnnual meetingRetrospective match case controlFast trackClinical oncologyPrivate securities litigation reform actAnnual report